Format

Send to

Choose Destination
Cancer Lett. 2014 Sep 28;352(1):113-25. doi: 10.1016/j.canlet.2013.09.016. Epub 2013 Sep 17.

A personalized view on cancer immunotherapy.

Author information

1
Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.
2
Laboratory of Molecular and Cellular Therapy, Department of Immunology and Physiology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103/E, 1090 Brussels, Belgium.
3
Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium. Electronic address: Koen.Raemdonck@UGent.be.

Abstract

Recent progress in cancer immunotherapy has resulted in complete responses in patients refractory to current standard cancer therapies. However, due to tumor heterogeneity and inter-individual variations in anti-tumor immunity, only subsets of patients experience clinical benefit. This review highlights the implementation of a personalized approach to enhance treatment efficacy and reduce side effects, including the identification of tumor-specific antigens for cancer vaccination and adoptive T cell therapies. Furthermore, together with the current advances and promising clinical outcomes of combination cancer (immuno-)therapies, the screening for predictive biomarkers in a patient-specific manner is emphasized.

KEYWORDS:

Adoptive T cell therapy; Cancer immunotherapy; Personalized medicine; Predictive biomarkers; Tumor antigens; Tumor heterogeneity

PMID:
24051308
DOI:
10.1016/j.canlet.2013.09.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center